Literature DB >> 31711342

Test-retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer's disease.

Cristian Salinas1, Talakad G Lohith2, Ajay Purohit1, Arie Struyk3, Cyrille Sur2, Idriss Bennacef2, John Beaver1, Laurent Martarello1.   

Abstract

[18F]MK-6240 is a selective, high-affinity PET radiotracer for imaging neurofibrillary tangles (NFT) in Alzheimer's disease (AD). Herein, we report test-retest (T-RT) reproducibility of [18F]MK-6240 in AD and healthy volunteers (HV). Twelve subjects with AD and three cognitively normal HV were enrolled in the study and dynamically scanned for 150 min with [18F]MK-6240 under a T-RT protocol. Two radioactivity doses were investigated: 165 ± 3 MBq (n = 6) and 300 ± 40 MBq (n = 9). Serial arterial blood samples were taken for each scan to obtain metabolite-corrected input functions. Following intravenous administration of [18F]MK-6240, the tracer rapidly partitioned into the brain and its heterogenous distribution pattern was consistent with known NFT pathology in AD. In contrast, uptake in HV was low and uniform across the brain parenchyma. Across all subjects, average T-RT variabilities in NFT-rich regions were ∼21%, ∼14% and ∼6% for various quantitative metrics: total distribution volume (VT), binding potential (BPND), and standardized uptake ratio (SUVR90-120), respectively. No significant differences in SUVR T-RT variability were observed between the high and low injected radioactivity groups (5.6% and 6.1%, respectively). This work suggests [18F]MK-6240 has adequate SUVR T-RT characteristics supporting the use of this outcome in future studies.

Entities:  

Keywords:  Alzheimer’s disease; PET; [18F]MK-6240; tau; test–retest

Year:  2019        PMID: 31711342      PMCID: PMC7585918          DOI: 10.1177/0271678X19887781

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  13 in total

1.  Simplified reference tissue model for PET receptor studies.

Authors:  A A Lammertsma; S P Hume
Journal:  Neuroimage       Date:  1996-12       Impact factor: 6.556

2.  cGMP production of the radiopharmaceutical [18 F]MK-6240 for PET imaging of human neurofibrillary tangles.

Authors:  Thomas Lee Collier; Daniel L Yokell; Eli Livni; Peter A Rice; Sofie Celen; Kim Serdons; Ramesh Neelamegam; Guy Bormans; Dawn Harris; Abbas Walji; Eric D Hostetler; Idriss Bennacef; Neil Vasdev
Journal:  J Labelled Comp Radiopharm       Date:  2017-03-23       Impact factor: 1.921

3.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

Authors:  Adam J Schwarz; Peng Yu; Bradley B Miller; Sergey Shcherbinin; James Dickson; Michael Navitsky; Abhinay D Joshi; Michael D Devous; Mark S Mintun
Journal:  Brain       Date:  2016-03-02       Impact factor: 13.501

4.  Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions.

Authors:  R V Parsey; M Slifstein; D R Hwang; A Abi-Dargham; N Simpson; O Mawlawi; N N Guo; R Van Heertum; J J Mann; M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2000-07       Impact factor: 6.200

5.  Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).

Authors:  Abbas M Walji; Eric D Hostetler; Harold Selnick; Zhizhen Zeng; Patricia Miller; Idriss Bennacef; Cristian Salinas; Brett Connolly; Liza Gantert; Marie Holahan; Stacey O'Malley; Mona Purcell; Kerry Riffel; Jing Li; Jaume Balsells; Julie A OBrien; Stacey Melquist; Aileen Soriano; Xiaoping Zhang; Aimie Ogawa; Serena Xu; Elizabeth Joshi; Joseph Della Rocca; Fred J Hess; Joel Schachter; David Hesk; David Schenk; Arie Struyk; Kerim Babaoglu; Talakad G Lohith; Yaode Wang; Kun Yang; Jianmin Fu; Jeffrey L Evelhoch; Paul J Coleman
Journal:  J Med Chem       Date:  2016-05-05       Impact factor: 7.446

6.  Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles.

Authors:  Eric D Hostetler; Abbas M Walji; Zhizhen Zeng; Patricia Miller; Idriss Bennacef; Cristian Salinas; Brett Connolly; Liza Gantert; Hyking Haley; Marie Holahan; Mona Purcell; Kerry Riffel; Talakad G Lohith; Paul Coleman; Aileen Soriano; Aimie Ogawa; Serena Xu; Xiaoping Zhang; Elizabeth Joshi; Joseph Della Rocca; David Hesk; David J Schenk; Jeffrey L Evelhoch
Journal:  J Nucl Med       Date:  2016-05-26       Impact factor: 10.057

7.  The simplified reference tissue model: model assumption violations and their impact on binding potential.

Authors:  Cristian A Salinas; Graham E Searle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-26       Impact factor: 6.200

8.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method.

Authors:  M E Phelps; S C Huang; E J Hoffman; C Selin; L Sokoloff; D E Kuhl
Journal:  Ann Neurol       Date:  1979-11       Impact factor: 10.422

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls.

Authors:  Tobey J Betthauser; Karly A Cody; Matthew D Zammit; Dhanabalan Murali; Alexander K Converse; Todd E Barnhart; Charles K Stone; Howard A Rowley; Sterling C Johnson; Bradley T Christian
Journal:  J Nucl Med       Date:  2018-05-18       Impact factor: 10.057

View more
  9 in total

1.  Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern.

Authors:  Greet Vanderlinden; Jenny Ceccarini; Thomas Vande Casteele; Laura Michiels; Robin Lemmens; Eric Triau; Kim Serdons; Jos Tournoy; Michel Koole; Mathieu Vandenbulcke; Koen Van Laere
Journal:  Mol Psychiatry       Date:  2022-07-06       Impact factor: 15.992

Review 2.  Novel Tracers and Radionuclides in PET Imaging.

Authors:  Christian Mason; Grayson R Gimblet; Suzanne E Lapi; Jason S Lewis
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

Review 3.  Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  Gérard N Bischof; Alessandra Dodich; Marina Boccardi; Thilo van Eimeren; Cristina Festari; Henryk Barthel; Oskar Hansson; Agneta Nordberg; Rik Ossenkoppele; Osama Sabri; B Frisoni G Giovanni; Valentina Garibotto; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-16       Impact factor: 9.236

4.  Patterns of tau pathology identified with 18 F-MK-6240 PET imaging.

Authors:  William Charles Kreisl; Patrick J Lao; Aubrey Johnson; Zeljko Tomljanovic; Julia Klein; Krista Polly; Benjamin Maas; Krystal K Laing; Anthony G Chesebro; Kay Igwe; Qolamreza R Razlighi; Lawrence S Honig; Xinyu Yan; Seonjoo Lee; Akiva Mintz; José A Luchsinger; Yaakov Stern; D P Devanand; Adam M Brickman
Journal:  Alzheimers Dement       Date:  2021-05-31       Impact factor: 16.655

5.  Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects.

Authors:  Alexandra Gogola; Davneet S Minhas; Victor L Villemagne; Ann D Cohen; James M Mountz; Tharick A Pascoal; Charles M Laymon; N Scott Mason; Milos D Ikonomovic; Chester A Mathis; Beth E Snitz; Oscar L Lopez; William E Klunk; Brian J Lopresti
Journal:  J Nucl Med       Date:  2021-04-16       Impact factor: 11.082

6.  Impact of meningeal uptake and partial volume correction techniques on [18F]MK-6240 binding in aMCI patients and healthy controls.

Authors:  Nathalie Mertens; Laura Michiels; Greet Vanderlinden; Mathieu Vandenbulcke; Robin Lemmens; Koen Van Laere; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2022-01-21       Impact factor: 6.960

Review 7.  Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective.

Authors:  Maria Ricci; Andrea Cimini; Riccardo Camedda; Agostino Chiaravalloti; Orazio Schillaci
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

Review 8.  Imaging pathological tau in atypical parkinsonisms: A review.

Authors:  Anastassia M Mena; Antonio P Strafella
Journal:  Clin Park Relat Disord       Date:  2022-07-16

9.  A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240.

Authors:  Ronald Boellaard; Michel Koole; Guilherme D Kolinger; David Vállez García; Talakad G Lohith; Eric D Hostetler; Cyrille Sur; Arie Struyk
Journal:  EJNMMI Res       Date:  2021-05-27       Impact factor: 3.138

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.